末端肥大症の病態並びに治療に関する研究

DOI 機関リポジトリ Web Site Web Site

書誌事項

タイトル別名
  • Studies on pathophysiology and treatment in patients with active acromegaly
  • 末端肥大症の病態並びに治療に関する研究-1-各種薬物負荷に対する血漿成長ホルモンの反応性に関する研究
  • マッタン ヒダイショウ ノ ビョウタイ ナラビニ チリョウ ニカンスルケンキュ
  • 第一編 各種薬物負荷に対する血漿成長ホルモンの反応性に関する研究
  • Part I. Studies on pathophysiology of active acromegaly

この論文をさがす

抄録

The effects of several drugs on the release of human growth hormone (hGH) were investigated, and the following results were obtained.<br>1). Single intravenous injection of insulin or drop infusion of L-arginine provocated an increase in plasma hGH in 3 out of 8 and 4 out of 6 patients with active acromegaly, respectively.<br>2). Single intravenous injection of thyrotropin-releasing hormone (TRH) or luteinizing hormone-releasing hormone (LH-RH) provoked a prompt increase in plasma hGH in 7 out of 13 and 4 out of 10 patients with acromegaly, respectively, whereas no significant change in plasma hGH was observed in normal subjects.<br>3). Plasma hGH levels decreased significantly within 30 min after an injection of glucagon in 7 out of 10 patients with acromegaly.<br>4). Single oral administration of L-dopa or 2-Br-α-ergocryptine (CB-154) induced a significant fall in hGH levels in patients with acromegaly, but a significant rise in plasma hGH in normal subjects.<br>5). The hGH response to L-dopa was compared before and after incomplete removal of pituitary adenoma in 2 patients with active acromegaly. Before surgery L-dopa decreased the plasma hGH levels, while after surgery L-dopa caused a significant increase in plasma hGH levels in both patients. At 10 months after surgery L-dopa decreased the plasma hGH levels again in one patient despite a low basal hGH concentration.<br>These results suggest that the primary disorder of the acromegaly resides in the pituitary level at least in some patients with acromegaly.

収録刊行物

詳細情報 詳細情報について

問題の指摘

ページトップへ